Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy

Helicobacter

Volumn 12, Issue 4, 2007, Pages 359-363

  Cheng, Hsiu Chi ^a   Chang, Wei Lun ^a   Chen, Wei Ying ^a   Yang, Hsiao Bai ^a   Wu, Jiunn Jong ^a   Sheu, Bor Shyang ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Clarithromycin; H. pylori; Levofloxacin; Second line therapy; Triple therapy

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIARRHEA; DRUG TREATMENT FAILURE; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UREA BREATH TEST; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CONSTIPATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; NAUSEA; OFLOXACIN; TREATMENT OUTCOME; VOMITING;

HELICOBACTER PYLORI;

EID: 34547594433     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00507.x     Document Type: Article

References (26)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002 16 : 167 80.
2. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics: the MACH1 study. Helicobacter 1996 1 : 138 44.
3. Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999 13 : 289 95.
4. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999 13 : 703 12.
5. Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multi-step strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000 14 : 79 83.
6. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies. Gastroenterology 1999 116 : 248 53.
7. Huang AH, Sheu BS, Yang HB, et al. Antimicrobial resistance of H. pylori to the outcome of one-week lansoprazole-based triple therapy. J Formosan Med Assoc 2000 90 : 704 9.
8. Sheu BS, Wu JJ, Yang HB, Wu HW, Lin MT. Lactobacillus and bifidobacteria containing yogurt can improve the drug compliance of triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 16 : 1669 75.
9. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002 7 (Suppl. 1 43 9.
10. Georgopoulos SD, Ladas SD, Laratapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002 16 : 569 75.
11. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance of failure of macrolide-nitromidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002 16 : 315 24.
12. Sheu BS, Cheng HC, Kao AW, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr 2006 83 : 864 9.
13. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003 18 : 347 53.
14. Kao AW, Cheng HC, Sheu BS, et al. Post-treatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy. Gen Intern Med 2005 20 : 139 42.
15. errits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006 6 : 699 709.
16. ong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 421 7.
17. Giannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006 23 : 281 7.
18. Gatta L, Zullo A, Perna F, et al. A. 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005 22 : 45 9.
19. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005 21 : 783 7.
20. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006 24 : 1469 74.
21. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006 101 : 1985 90.
22. Gisbert JP. Rescue therapy with levofloxacin after multiple H. pylori treatment failures. Aliment Pharmacol Ther 2005 22 : 653 4.
23. Coelho LG. Rescue therapy with levofloxacin after multiple H. pylori treatment failures: Author's reply. Aliment Pharmacol Ther 2005 22 : 654 5.
24. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 5.
25. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003 47 : 3942 4.
26. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 96.